170506 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
BIOMARKERS
#2ASSAY AND METHODS FOR DRUG DISCOVERY
#3METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF
#4AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES
#5METHODS FOR DETECTING AND TREATING CEREBRAL CAVERNOUS MALFORMATION
#6TNFR2 BINDING MOLECULE AND USE THEREOF
#7ANTI-POLYUBIQUITIN MULTISPECIFIC ANTIBODIES
#8EARLY DIAGNOSIS OF INFECTIONS
#9POINT OF SERVICE METHOD OF DETECTING, DIAGNOSING AND FOLLOWING CANCER AND OTHER PROLIFERATIVE CONDITIONS
#10Cardiovascular Disease
#11Blood Test to Screen Out Parkinson's Disease
#12A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE
#13IN VITRO METHOD FOR OBTAINING CLINICAL DATA IN PATIENTS SUFFERING FROM AN INFLAMMATORY DISEASE
#14Early diagnosis of infections
#15Agonistic anti-tumor necrosis factor receptor 2 antibodies
#16BIOMARKERS
#17Anti-TNFR2 antibody and use thereof
#18Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#19Anti-GITR antibodies for cancer diagnostics
#20Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#21Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#22CHIMERIC RECEPTORS, BIOSENSOR HOST CELLS AND METHODS/USES THEREOF
#23MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS
#24Blood Test for Screening Out Amyloid and Alzheimers Disease Presence
#25System and method for determining risk of diabetes based on biochemical marker analysis
#26AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES
#27NOVEL ANTI-TNFRSF21 ANTIBODIES AND METHODS OF USE
#28Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
#29Method of monitoring the efficacy of the anti-clever-1 therapy in cancer
#30Method for the selection of antibodies against BCMA
#31Anti-GITR antibodies for cancer diagnostics
#32USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING
#33Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
#34Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#35ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#36Biomarker-based methods for aiding the diagnosis of stroke
#37Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
#38Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#39Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#40Method for aiding differential diagnosis of stroke
#41Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
#42NOVEL GROUPS OF BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE
#43Bispecific antibodies against CD3 and BCMA
#44Method for the selection of antibodies against BCMA
#45Diagnosis and risk stratification of bladder cancer
#46MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS
#47Biomarker of renal dysfunction
#48Biomarker of renal dysfunction
#49High throughput sensitization detection devices and methods
#50Use of RANK/RANKL antagonists for treating muscular dystrophy
#51Use of tumor Fas expression to determine response to anti-cancer therapy
#52Agents and methods related to screening for resistance to DR5 and reducing resistance to DR5 agonists
#53Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
#54TNF-α antagonists containing IGFBP5
#55TNF-α binding proteins
#56NOVEL GROUPS OF BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE
#57Diagnosis and/or prognosis of renal dysfunction
#58OSTEOPROTEGERIN
#59Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
#60DOMINANT NEGATIVE LIGAND DRUG DISCOVERY SYSTEM